Table 3 Infarct size in patients with SGLT2-I versus patients with other OAD agents alone
Total (N = 583) | SGLT2-I users (N = 98) | Non-SGLT-I users (N = 485) | p value | |
|---|---|---|---|---|
Hospital Admission | ||||
Q wave, n (%) | 131 (25.2) | 18 (23.4) | 113 (25.6) | 0.615 |
Admission LVEDV, ml | 108 ± 33 | 106 ± 35 | 108 ± 33 | 0.582 |
Admission LVEF, % | 47 ± 11 | 48 ± 10 | 47 ± 11 | 0.161 |
RWMA, n (%) | 491 (84.2) | 81 (82.7) | 410 (84.5) | 0.641 |
I hs-TnI, ng/L | 210 [44–1431] | 131 [33–773] | 240 [50–1964] | 0.003 |
II hs-TnI, ng/L | 1411 [338–10.032] | 635 [165–2108] | 1842 [370–13.447] | < 0.001 |
III hs-TnI, ng/L | 1306 [390–11.028] | 441 [160–1120] | 2356 [566–18.056] | < 0.001 |
hs-TnI max, ng/L | 2438 [591–16.227] | 901 [307–2543] | 3445 [710–9223] | < 0.001 |
Hospital Discharge | ||||
LVEDV, ml | 108 ± 36 | 103 ± 29 | 110 ± 38 | 0.261 |
LVEF, % | 49 ± 10 | 53 ± 19 | 48 ± 11 | 0.001 |
RWMA, n (%) | 454 (78) | 64 (65.3) | 390 (80.6) | 0.001 |
ST resolution, n (%) | 187 (67) | 42 (87.5) | 146 (63.2) | 0.001 |